BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: Schering-Plough Corporation (SGP) Gets Approval For Noxafil


9/18/2006 5:11:23 PM

September 18, 2006 -- Schering-Plough won FDA approval for anti-fungal drug Noxafil; GlaxoSmithKline asked the FDA to approve cancer drug Tykerb; Schering out-licensed the opthalmological rights to its glucocorticoid receptor agonist; Pfizer in-licensed several Alzheimer’s disease drug candidates from TransTech Pharma; Cell Therapeutics partnered cancer drug Xyotax with Novartis; Nektar won orphan designation in Europe for a fungal infection drug; NeoPharm released positive long-term data on its brain cancer candidate; Cytogen cited a journal publication detailing positive data on Quadramet; MannKind released positive results from its inhaled insulin product; ZymoGenetics said its recombinant human thrombin passed a Phase III trial; Serono optioned infertility drugs from Syntonix Pharma; Angiotech Pharma reported its Vascular Wrap was effective in pre-clinical testing; and Aastrom released positive long-term data on its Tissue Repair Cells. At the close, the Centient Biotech 200™ was higher by a quarter of a point at 3735.11, an increase of .01%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES